Akero Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	31.07	29.87	19.13	15.24	8.61	1.9	1.08
Research & Development	141.8	85.28	81.76	64.92	37.05	11.88	3.49
Operating Expenses	172.87	115.16	100.89	80.15	45.65	13.78	4.56
Operating Income	-172.87	-115.16	-100.89	-80.15	-45.65	-13.78	-4.56
Interest Expense / Income	3.1	0.74	0	0	0	0	0
Other Expense / Income	-24.21	-3.86	-0.11	-0.95	-1.9	67.94	-
Pretax Income	-151.76	-112.03	-100.78	-79.21	-43.76	-81.71	-4.56
Net Income	-151.76	-112.03	-100.78	-79.21	-43.76	-81.71	-4.56
Preferred Dividends	0	0	0	0	0	0.52	0.21
Net Income Common	-151.76	-112.03	-100.78	-79.21	-43.76	-82.23	-4.78
Shares Outstanding (Basic)	53	39	35	31	15	0	-
Shares Outstanding (Diluted)	53	39	35	31	15	0	-
Shares Change	34.84%	11.94%	10.69%	108.77%	14474.75%	-	-
EPS (Basic)	-2.89	-2.87	-2.89	-2.52	-2.90	-795.28	-
EPS (Diluted)	-2.89	-2.87	-2.89	-2.52	-2.90	-795.28	-
Free Cash Flow	-145.37	-92.52	-79.68	-70.95	-35.63	-4.63	-4.38
Free Cash Flow Per Share	-2.77	-2.37	-2.29	-2.25	-2.36	-44.73	-
EBITDA	-148.4	-111.03	-100.53	-78.99	-43.76	-81.71	-4.56
Depreciation & Amortization	0.26	0.26	0.24	0.21	0	0	0
EBIT	-148.66	-111.29	-100.78	-79.21	-43.76	-81.71	-4.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).